Jaypirca is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine.
Jaypirca was approved based on how many people responded to treatment. Studies are ongoing to confirm the benefit of Jaypirca for this use.
It is not known if Jaypirca is safe and effective in children.
SELECT SAFETY INFORMATION
Warnings - Jaypirca may cause serious side effects, including:
Infections. Infections can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your doctor may prescribe certain medicines if you have an increased risk of getting infections. Tell your doctor right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment.
A new way* to help adults with previously treated MCL
Jaypirca is a first-of-its-kind* treatment for relapsed MCL
*Jaypirca is the only FDA-approved noncovalent BTK inhibitor.
With Jaypirca, you can continue to treat your MCL and focus on what matters most. When your MCL comes back or gets worse, Jaypirca may work after you stop a previous BTK inhibitor.